Produits et services

Chemical, biological and analytical preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, other than for medical or veterinary use. Diagnostic, therapeutic, biological, chemical, analytical and biochemical preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, in particular for diagnostic and therapeutic applications, pharmaceutical compositions for the diagnosis and treatment of cancer and eye diseases. Scientific, technological and industrial services and research, in particular in the therapeutic, diagnostic, pharmaceutical, analytical or biochemical field; services and research for identification, further development and application of diagnostic, therapeutic, biochemical, pharmaceutical or analytical goods; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.

Abrégé

The present invention relates to novel ligands for affinity chromatography, in particular purification of antibodies. The novel ligands are immunoglobulin (Ig) binding proteins with superior properties for highly efficient purification methods for antibodies (immunoglobulins). The invention further relates to affinity matrices comprising the ligands of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/245 - Escherichia (G)

Abrégé

The present invention relates to new ubiquitin derived molecules that bind specific to Fibroblast Activation Protein (FAP). The invention further refers to FAP binding ubiquitin derived molecules (Affilin®) proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover such FAP binding proteins for a use in medicine, for example, for a use in diagnosis (including imaging) or treatment of FAP related tumors.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to new proteins that are specific for Programmed (Cell) Death Ligand 1 (PD-L1). The PD-L1 specific proteins of the invention bind with high affinity to human and mouse PD-L1. The invention further refers to PD-L1 specific proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PD-L1 specific binding proteins in medicine, for example, in diagnosis and therapy of PD-L1 related cancer.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• G01N 33/575 -

Abrégé

Immunoglobulin (Ig) binding proteins having one or more domains having highly hydrophobic amino acids with branched side chains (Iso, Leu, Val), or aromatic amino acids (Tyr, Phe, or Trp) corresponding to position 4 or 6 or 8 of the Ig binding protein of SEQ ID NO: 1 or functionally similar proteins are provided. The disclosed proteins have superior properties for highly efficient purification methods for antibodies (immunoglobulins), for example, the proteins have high binding capacity and high chemical stability. Also provided are affinity matrices that include the disclosed Ig binding proteins, uses of these Ig binding proteins and/or affinity matrices for affinity purification of immunoglobulins, and methods for affinity purification using the disclosed Ig binding proteins.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; services and research and development work in the field of chromatography; services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, rna and test kits; services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; services and research and development work in the field of chromatography; services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, rna and test kits; services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; services and research and development work in the field of chromatography; services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, rna and test kits; services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Abrégé

The present invention relates to a novel affinity separation matrix that comprises novel binding ligands for double stranded RNA (dsRNA) and the use of said affinity separation matrix for purifying ribonucleic acid preparations. The present invention further relates to a method of purifying ribonucleic acid preparations and a kit for use in a method of purifying ribonucleic acid preparations, implementing the novel affinity separation matrix. The present disclosure also relates to a method of production of a single-stranded RNA (ssRNA) preparation.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; services and research and development work in the field of chromatography; services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, rna and test kits; services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; services and research and development work in the field of chromatography; services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, rna and test kits; services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; services and research and development work in the field of chromatography; services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, rna and test kits; services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Abrégé

The present invention relates to novel affinity ligands that bind to human tissue plasminogen activator (tPA). The novel affinity ligands of the present invention are powerful tools because they allow efficient purification methods for human tPA via affinity chromatography. In particular, the affinity ligands are powerful in the purification of recombinant human tPA that was produced in Chinese hamster ovary cells because the affinity ligands of the invention do not detectably bind to hamster tPA. Accordingly, the present invention also relates to a novel process of isolating and purifying tPA, specifically tPA from CHO cells.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 9/72 - Urokinase
• C12Q 1/56 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des facteurs de coagulation du sang, p. ex. faisant intervenir la thrombine, la thromboplastine, le fibrinogène
• G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use; Solid carriers with coupled proteins, polypeptides, peptides for use in purifying substances (including proteins, polypeptides, peptides, ribonucleic acids, nucleic acids, viral vectors, virus-like particles or cells), including for use in production and cleaning processes, including chromatography, not for medical purposes; Materials for use in production and purifying processes, including proteins, polypeptides, peptides, antibodies, fusion processes, enzymes, hormones, blood factors, vaccines, ribonucleic acids, nucleic acids, viral vectors, virus-like particles or cells; Including materials for use in the production of proteins, polypeptides, peptides, antibodies, fusion processes, enzymes, hormones, blood factors, vaccines, ribonucleic acids, nucleic acids, viral vectors, virus-like particles or cells. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, RNA and test kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Abrégé

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains having highly hydrophobic amino acids with branched side chains (Iso, Leu, Val), or aromatic amino acids (Tyr, Phe, or Trp) corresponding to position 4 or 6 or 8 of the Ig binding protein of SEQ ID NO: 1 or functionally similar proteins. The novel proteins have superior properties for highly efficient purification methods for antibodies (immunoglobulins), for example, the proteins have high binding capacity and high chemical stability. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)

Abrégé

The present invention relates to new proteins that are specific for human epidermal growth factor kinase receptor 3 (ERB-B3 receptor tyrosine kinase 3, Her3). The Her3 specific proteins of the invention bind with high affinity to human Her3. The invention further refers to Her3 specific proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these Her3 specific binding proteins in medicine, for example, in diagnosis and therapy of Her3 related cancer.

Classes IPC  ?

• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to novel ligands for affinity chromatography for the purification of antibodies. The novel ligands are immunoglobulin (Ig) binding proteins with superior properties for highly efficient purification methods for antibodies (immunoglobulins) in terms of extreme alkaline stability of the ligands combined with mild pH elution conditions for the antibodies. The invention further relates to affinity matrices comprising the novel ligands of the invention. The invention also relates to a use of these ligands or affinity matrices comprising these ligands for affinity purification of immunoglobulins and to methods of affinity purification.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 17/10 - Peptides immobilisés sur, ou dans, un support organique le support étant un hydrate de carbone

Abrégé

The invention relates to a fusion protein that comprises at least one albumin binding moiety and further comprises a tumor targeting moiety. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications.

Classes IPC  ?

• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of cleaning, identification, screening and manufacture of the following goods: analytic goods, Biochemical products, Pharmaceuticals, diagnostic products, Therapeutic products, in particular Proteins, Antibodies, Fusion proteins, Enzymes, Hormones, Blood factors, Vaccines, Virus vectors, virus-like particles, Cells, RNA and testing kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of cleaning, identification, screening and manufacture of the following goods: analytic goods, Biochemical products, Pharmaceuticals, diagnostic products, Therapeutic products, in particular Proteins, Antibodies, Fusion proteins, Enzymes, Hormones, Blood factors, Vaccines, Virus vectors, virus-like particles, Cells, RNA and testing kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological and analytical preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, other than for medical or veterinary use. Diagnostic, therapeutic, biological, chemical, analytical and biochemical preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, in particular for diagnostic and therapeutic applications, pharmaceutical compositions for the diagnosis and treatment of cancer and eye diseases. Scientific, technological and industrial services and research, in particular in the therapeutic, diagnostic, pharmaceutical, analytical or biochemical field; Services and research for identification, further development and application of diagnostic, therapeutic, biochemical, pharmaceutical or analytical goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.

Produits et services

Chemical, biological and analytical preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, other than for medical or veterinary use. Diagnostic, therapeutic, biological, chemical, analytical and biochemical preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, in particular for diagnostic and therapeutic applications, pharmaceutical compositions for the diagnosis and treatment of cancer and eye diseases. Scientific, technological and industrial services and research, in particular in the therapeutic, diagnostic, pharmaceutical, analytical or biochemical field; Services and research for identification, further development and application of diagnostic, therapeutic, biochemical, pharmaceutical or analytical goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.

Abrégé

The present invention relates to new hyaluronic acid binding proteins. The invention refers to new engineered fusion proteins for use in treating disorders of the eye or the joints. The fusion proteins comprise a subunit that specifically binds to hyaluronic acid. In addition to the hyaluronic acid binding protein, the new fusion proteins comprise a protein therapeutically effective in diseases of the eye or of joints. The fusion proteins are particularly well-suited for medical applications that require extended half-life of eye specific therapeutic proteins.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 27/02 - Agents ophtalmiques
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance

Abrégé

The present invention relates to novel proteins that specifically bind to the ferritin. The novel proteins of the present invention are advanced and powerful tools because they allow precise purification methods of ferritin, for example via affinity chromatography. Further, the binding protein for ferritin is useful for methods to analyze the presence of ferritin.

Classes IPC  ?

• C07K 14/795 - Peptides contenant des cycles porphyrine ou corrine
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, RNA and test kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, RNA and test kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, RNA and test kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The invention relates to fusion proteins that comprise at least one serum albumin binding protein. The fusion proteins of the present invention can be characterized by (i) the high thermal stability (in particular, a Tm above 70 °C), (ii) the high binding affinity for human, mouse, and rat serum albumin (in the two digit nanomolar range), and (iii) the long stability in human and mouse serum (at least 48 h). The invention also relates to the use of the fusion protein or of compositions comprising the fusion protein for medical applications.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

gp64 is the major envelope glycoprotein of baculoviruses. The present invention relates to novel proteins that specifically bind to the baculovirus envelope protein gp64. The novel proteins of the present invention are advanced and powerful tools because they allow precise capturing of gp64 in affinity chromatography. The gp64 binding proteins are particularly useful tools within the process of protein production (e.g. vaccine production) to provide for gp64 free samples. Further, the binding protein for gp64 are useful for methods to analyze the presence of gp64.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/245 - Escherichia (G)
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to novel affinity ligands for the affinity purification of ubiquitin muteins. In particular, the alkaline stable affinity ligands are useful for affinity chromatography purification and detection of a ubiquitin mutein (such as Affilin® protein). The novel affinity ligands for a ubiquitin mutein are based on artificial mosaic proteins of Protein A-like structure. The affinity ligands of the invention can be used for the purification and detection of ubiquitin muteins.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to new ubiquitin derived molecules that are specific for Programmed Death Ligand 1 (PD-L1). The PD-L1 specific molecules of the invention inhibit the interaction between PD1 and PD-L1. The invention further refers to PD-L1 specific Affilin® proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PD-L1 binding proteins in medicine, for example, in diagnosis and therapy of PD-L1 related cancer.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 49/00 - Préparations pour examen in vivo
• A61K 51/08 - Peptides, p. ex. protéines
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to new engineered fusion proteins with for use in treating disorders of the eye. In particular, the new fusion proteins are capable of binding both VEGF-A and Type II collagen. The fusion proteins comprise a subunit that specifically binds to Type II collagen which is a major component of the fibrillary structure of the vitreous humor of the eye. In addition to the Type II collagen binding protein, the new fusion proteins comprise a protein specific for VEGF-A and therapeutically effective in eye diseases. The invention further relates to the new fusion proteins for a use in the treatment of neovascular eye diseases.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 27/02 - Agents ophtalmiques

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Abrégé

The present invention relates to novel ligands for affinity chromatography, in particular purification of antibodies. The novel ligands are immunoglobulin (Ig) binding proteins with superior properties for highly efficient purification methods for antibodies (immunoglobulins). The invention further relates to affinity matrices comprising the ligands of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to new proteins that are specific for Programmed (Cell) Death Ligand 1 (PD-L1). The PD-L1 specific proteins of the invention bind with high affinity to human and mouse PD-L1. The invention further refers to PD-L1 specific proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PD-L1 specific binding proteins in medicine, for example, in diagnosis and therapy of PD-L1 related cancer.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The invention relates to a fusion protein that comprises at least one albumin binding moiety and further comprises a tumor targeting moiety. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/82 - Produits de traduction des oncogènes
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The invention relates to a fusion protein that comprises at least one albumin binding moiety and further comprises a tumor targeting moiety. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications.

Classes IPC  ?

• C07K 14/82 - Produits de traduction des oncogènes
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to new type II collagen alpha I chain specific binding proteins. The invention further refers to type II collagen binding proteins further fused to or conjugated to a therapeutically or diagnostically active component. Further aspects of the invention cover the use of these type II collagen binding proteins in medicine.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The present invention relates to novel proteins that specifically bind to complement factor H (CFH). The present invention further relates to methods of production of CFH, in particular purification of CFH. The novel CFH binding ligands of the present invention are advanced and powerful tools because they allow methods of purification of CFH via affinity chromatography.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The present disclosure relates to new serum stable non-immunoglobulin binding proteins based on ubiquitin scaffold that are highly specific for membrane-bound receptor tyrosine kinase (Her2). The disclosure provides novel specific recombinant Her2 binding proteins with high serum stability essentially combined with high temperature stability and high affinity for Her2 for uses in medical applications for diagnosis or therapy of cancer with Her2 overexpression, in particular, for radiopharmaceutical applications.

Classes IPC  ?

• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif

Abrégé

The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona vims 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to novel proteins that specifically bind to the ferritin. The novel proteins of the present invention are advanced and powerful tools because they allow precise purification methods of ferritin, for example via affinity chromatography. Further, the binding protein for ferritin is useful for methods to analyze the presence of ferritin.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective

Abrégé

The present invention relates to novel engineered artificial immunoglobulin (Ig) binding polypeptides comprising three domains and two linkers. The invention further relates to affinity matrices comprising these artificial Ig binding molecules of the invention. The novel Ig binding proteins are particularly useful for the affinity purification of proteins requiring elution at a higher pH (in particular higher than pH 4.2). The invention also relates to a use of the novel Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the novel Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 17/12 - Cellulose ou ses dérivés

Abrégé

The present invention relates to new ubiquitin derived molecules that bind specific to Fibroblast Activation Protein (FAP). The invention further refers to FAP binding ubiquitin derived molecules (Affilin®) proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover such FAP binding proteins for a use in medicine, for example, for a use in diagnosis (including imaging) or treatment of FAP related tumors.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine

Abrégé

The present invention relates to new ubiquitin derived molecules that bind specific to Fibroblast Activation Protein (FAP). The invention further refers to FAP binding ubiquitin derived molecules (Affilin®) proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover such FAP binding proteins for a use in medicine, for example, for a use in diagnosis (including imaging) or treatment of FAP related tumors.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61P 35/00 - Agents anticancéreux
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine

Abrégé

gp64 is the major envelope glycoprotein of baculoviruses. The present invention relates to novel proteins that specifically bind to the baculovirus envelope protein gp64. The novel proteins of the present invention are advanced and powerful tools because they allow precise capturing of gp64 in affinity chromatography. The gp64 binding proteins are particularly useful tools within the process of protein production (e.g. vaccine production) to provide for gp64 free samples. Further, the binding protein for gp64 are useful for methods to analyze the presence of gp64.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Produits et services

Scientific, technological, and industrial research services all in the field of half-life modifying domains; scientific, technological, and industrial research services conducted in molecular biology, biotechnology and biochemical laboratories all in the field of half-life modifying domains

Abrégé

The present invention relates to the field of protein purification and relates in particular to novel proteins that bind to the soluble part of fibroblast growth factor receptor 3 (sFGFR3). The invention further relates to fusion proteins comprising novel proteins that bind to sFGFR3. In addition, the invention relates to affinity matrices comprising the sFGFR3 binding proteins of the invention. The invention also relates to a use of these sFGFR3 binding proteins or affinity matrices for affinity purification of sFGFR3 nd to methods of affinity purification of sFGFR3 using the sFGFR3 binding proteins of the invention. Further uses relate to analytical methods for the determination of SFGFR3 in liquids.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes

Abrégé

The present invention relates to novel affinity ligands for the affinity purification of ubiquitin muteins. In particular, the alkaline stable affinity ligands are useful for affinity chromatography purification and detection of a ubiquitin mutein (such as Affilin® protein). The novel affinity ligands for a ubiquitin mutein are based on artificial mosaic proteins of Protein A-like structure. The affinity ligands of the invention can be used for the purification and detection of ubiquitin muteins..

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Abrégé

The present invention relates to new engineered fusion proteins with for use in treating disorders of the eye. In particular, the new fusion proteins are capable of binding both VEGF- A and Type II collagen. The fusion proteins comprise a subunit that specifically binds to Type II collagen which is a major component of the fibrillary structure of the vitreous humor of the eye. In addition to the Type II collagen binding protein, the new fusion proteins comprise a protein specific for VEGF-A and therapeutically effective in eye diseases. The invention further relates to the new fusion proteins for a use in the treatment of neovascular eye diseases.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention relates to new ubiquitin derived molecules that are specific for Programmed Death Ligand 1 (PD-L1). The PD-L1 specific molecules of the invention inhibit the interaction between PD1 and PD-L1. The invention further refers to PD-L1 specific Affilin® proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PD-L1 binding proteins in medicine, for example, in diagnosis and therapy of PD-L1 related cancer.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 35/00 - Agents anticancéreux

Abrégé

Binding proteins that are specific for prostate specific membrane antigen (PSMA), multimers thereof, and conjugates thereof are described. Also described are PSMA binding proteins that include a diagnostically or therapeutically active component and/or a pharmacokinetics-modulating moiety, as well as methods for using the described PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to novel proteins that specifically bind to complement factor H (CFH). The present invention further relates to methods of production of CFH, in particular purification of CFH. The novel CFH binding ligands of the present invention are advanced and powerful tools because they allow methods of purification of CFH via affinity chromatography.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to new type II collagen alpha I chain specific binding proteins. The invention further refers to type II collagen binding proteins further fused to or conjugated to a therapeutically or diagnostically active component. Further aspects of the invention cover the use of these type II collagen binding proteins in medicine.

Classes IPC  ?

• A61P 27/02 - Agents ophtalmiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif

Produits et services

Biological, diagnostic, therapeutic, biochemical substances, active agents, and/or compositions for human medical, veterinary, and/or diagnostic use, in particular containing proteins, polypeptides, peptides or parts thereof; Pharmaceutical and veterinary preparations; Therapeutic agents [medical]; Biochemical therapeutic active agents. Scientific, technological and industrial services, Scientific, technological and industrial research, Especially, Relating to the following sectors: Pharmaceutical, therapeutic and diagnostic field; Services and research work for the further development and application of pharmaceutical, diagnostic and therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of human medical and veterinary diagnostics and treatment using molecular biological, biotechnological or biochemical, genetic engineering methods, and in the field of development of analytic, biochemical, pharmaceutical and diagnostic goods and test methods and test kits.

Produits et services

Biological, diagnostic, therapeutic, biochemical substances, active agents, and/or compositions for human medical, veterinary, and/or diagnostic use, in particular containing proteins, polypeptides, peptides or parts thereof; Pharmaceutical and veterinary preparations; Therapeutic agents [medical]; Biochemical therapeutic active agents. Scientific services and research, Technological services and research, Industrial services, Industrial research, Especially, Relating to the following sectors: Pharmacy, Biochemistry, Treatment, Diagnostics; Services and research work for the further development and application of biochemical, pharmaceutical, diagnostic and therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of human medical and veterinary diagnostics and treatment using molecular biological, biotechnological or biochemical, genetic engineering methods, and in the field of development of analytic, biochemical, pharmaceutical and diagnostic goods and test methods and test kits.

Abrégé

The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 14/305 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F)
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective

Abrégé

The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.

Produits et services

Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.

Abrégé

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains having highly hydrophobic amino acids with branched side chains (Iso, Leu, Val), or aromatic amino acids (Tyr, Phe, or Trp) corresponding to position 4 or 6 or 8 of the Ig binding protein of SEQ ID NO: 1 or functionally similar proteins. The novel proteins have superior properties for highly efficient purification methods for antibodies (immunoglobulins), for example, the proteins have high binding capacity and high chemical stability. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques

Abrégé

The present disclosure relates to new serum stable non-immunoglobulin binding proteins based on ubiquitin scaffold that are highly specific for membrane-bound receptor tyrosine kinase (Her2). The disclosure provides novel specific recombinant Her2 binding proteins with high serum stability essentially combined with high temperature stability and high affinity for Her2 for uses in medical applications for diagnosis or therapy of cancer with Her2 overexpression, in particular, for radiopharmaceutical applications.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes

Abrégé

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains having highly hydrophobic amino acids with branched side chains (Iso, Leu, Val), or aromatic amino acids (Tyr, Phe, or Trp) corresponding to position 4 or 6 or 8 of the Ig binding protein of SEQ ID NO: 1 or functionally similar proteins. The novel proteins have superior properties for highly efficient purification methods for antibodies (immunoglobulins), for example, the proteins have high binding capacity and high chemical stability. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

The present disclosure relates to new serum stable non-immunoglobulin binding proteins based on ubiquitin scaffold that are highly specific for membrane-bound receptor tyrosine kinase (Her2). The disclosure provides novel specific recombinant Her2 binding proteins with high serum stability essentially combined with high temperature stability and high affinity for Her2 for uses in medical applications for diagnosis or therapy of cancer with Her2 overexpression, in particular, for radiopharmaceutical applications.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.

Classes IPC  ?

• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• A61K 39/12 - Antigènes viraux

Abrégé

The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.

Classes IPC  ?

• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• A61K 39/12 - Antigènes viraux
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The present invention relates to novel engineered artificial immunoglobulin (Ig) binding polypeptides comprising three domains and two linkers. The invention further relates to affinity matrices comprising these artificial Ig binding molecules of the invention. The novel Ig binding proteins are particularly useful for the affinity purification of proteins requiring elution at a higher pH (in particular higher than pH 4.2). The invention also relates to a use of the novel Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the novel Ig binding proteins of the invention.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 1/12 - Procédés généraux de préparation de peptides par hydrolyse

Abrégé

The present invention relates to the field of protein purification and relates in particular to novel proteins that bind to the soluble part of fibroblast growth factor receptor 3 (sFGFR3). The invention further relates to fusion proteins comprising novel proteins that bind to sFGFR3. In addition, the invention relates to affinity matrices comprising the sFGFR3 binding proteins of the invention. The invention also relates to a use of these sFGFR3 binding proteins or affinity matrices for affinity purification of sFGFR3 and to methods of affinity purification of sFGFR3 using the sFGFR3 binding proteins of the invention. Further uses relate to analytical methods for the determination of SFGFR3 in liquids.

Classes IPC  ?

• C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Abrégé

The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective

Abrégé

The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Abrégé

The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

Provided are populations of polypeptides, wherein each member of the population of polypeptides includes or is an amino sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6. Also provided are methods for identifying polypeptides that bind to pre-selected target molecules, which in some embodiments can include providing a population of polypeptides as described herein, contacting the population of polypeptides with a pre-selected target molecule, and identifying a complex comprising at least one member of the population of polypeptides bound to the pre-selected target molecule; and populations of nucleic acid molecules that encode the presently disclosed populations of polypeptides.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Abrégé

The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.

Classes IPC  ?

• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Produits et services

Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific and technological services and research and industrial research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; research and development services in the field of identification and further use of biochemical, pharmaceutical, analytical or diagnostic products; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and research and development services in the field of identification and screening of pharmaceutically active components, and test methods and test kits.

Abrégé

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation

Abrégé

The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.

Classes IPC  ?

• A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The invention generally relates to targeted compounds for the site-specific coupling of chemical moieties. The present invention features a targeted compound for the coupling of chemical moieties comprising at least one targeting domain capable of binding a target, and at least one linking moiety of up to 80 amino acids, preferably alanine, proline, and serine, and at least one coupling site consisting of cysteine or a cysteine-rich peptide motif (CXC, CXXC, or CXXXC), and wherein said linking moiety connects the targeting domain and a coupling site and/or wherein a linking moiety connects two coupling sites. The invention further features fusion proteins with ubiquitin muteins (Affilin @) as targeting domain. The invention also relates to the use of the targeted compounds for medical applications, in treatment or diagnosis of diseases.

Classes IPC  ?

• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent

Produits et services

Chemical, biological, analytical and/or chromatographic substances, active ingredients and/or compositions, in particular containing proteins, polypeptides, peptides or parts thereof, in particular proteins, peptides or polypeptides fused to antibodies or antibody fragments, for industrial and scientific applications, not for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical and biochemical substances, active ingredients and/or compositions containing proteins, polypeptides and peptides, in particular proteins, peptides or polypeptides fused to antibodies or antibody fragments, for medical and veterinary applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic, biotechnological or biochemical methods.

Produits et services

Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions, namely, diagnostic preparations for medical and veterinary use, therapeutic preparations for medical and veterinary use, pharmaceutical preparations for the medical treatment of cancer, metabolic, inflammatory, skin, eye and cardiovascular diseases, and chemical reagents for medical or veterinary purposes Scientific, technological and industrial analysis services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; scientific and technological services and research relating thereto for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and research and development services in the field of identification, screening of pharmaceutically active components, and test methods and test kits

Produits et services

Chemicals, biological, analytical, and/or chromatographic preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial analysis service and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; scientific and technological services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.

Abrégé

The present disclosure relates to non-natural binding proteins comprising one or more non-natural immunoglobulin (Ig) binding domains wherein at least one non-natural lg-binding domain comprises the amino acid sequence X1 X2X3XiXsX5X7 XsQQX11AFYX1sX15LX1 sX19PX21 LX23X24X2sQRX28X2gf IQSLKDDPSXio SXi2Xi3Xi4LXi5EAXigKLXs2Xs3Xs4QXs5PX. The disclosure also relates to compositions such as affinity matrices comprising the non-natural Ig-binding proteins of the invention. Use of these Ig-binding proteins or of the compositions for affinity purification of immunoglobulins and to methods of affinity purification.

Classes IPC  ?

• C07K 16/46 - Immunoglobulines hybrides
• C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)

Produits et services

[ Chemicals, biological, analytical, and chromatographic preparations, active agents, and compositions, namely, proteins, polypeptides, and peptide substrates in raw form for scientific research, in particular for analysis of polypeptide, protein and peptide interaction, all of the foregoing not for medical or veterinary use ] [ Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and compositions, namely, diagnostic preparations for medical and veterinary purposes ] Scientific and technological analysis services, namely, scientific research in the pharmaceutical, diagnostic, analytical and biochemical field; scientific and technological services, namely, scientific research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; scientific laboratory services in the fields of molecular biological, biotechnological, biochemical or pharmaceutical products; scientific research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits

Abrégé

The present invention refers to new binding proteins based on di-ubiquitin modified in 12, 13, or 14 positions selected from positions R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, and T142 of di-ubiquitin and being able to bind specifically with high affinity to selected targets. Furthermore, the invention provides a method for the generation of said binding proteins. In addition, libraries encoding for said binding proteins based on di-ubiquitin muteins modified in 12, 13, or 14 positions selected from R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, and T142 are provided.

Classes IPC  ?

• C07K 14/245 - Escherichia (G)
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 38/00 - Préparations médicinales contenant des peptides

Produits et services

Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific and technological services and research and industrial research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.

Produits et services

Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific and technological services and research and industrial research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.

Abrégé

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding5 proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)